Does Tricare Cover Wegovy? Insurance Guide 2026
Weight management and diabetes care are critical health priorities, and medications like Wegovy have become a game-changer for many. As a GLP-1 receptor agonist, Wegovy (semaglutide) is FDA-approved for chronic weight management and type 2 diabetes, but navigating insurance coverage—especially with Tricare—can be complex. This guide breaks down Tricare’s policies on Wegovy, including eligibility, costs, and steps to secure coverage in 2026.
Does Tricare Cover Wegovy for Diabetes?
Tricare’s coverage of Wegovy for diabetes depends on specific clinical criteria and the plan tier. Wegovy, a higher-dose formulation of semaglutide, is chemically identical to Ozempic, which Tricare covers for type 2 diabetes under its pharmacy benefits. However, Wegovy is explicitly approved for chronic weight management, not diabetes, which complicates coverage. As of 2026, Tricare may approve Wegovy for diabetes only if the patient has a documented failure or intolerance to Ozempic or other preferred diabetes medications.
To qualify, providers must submit prior authorization demonstrating the patient’s A1C levels remain uncontrolled (≥7.0%) despite adherence to lifestyle changes and first-line therapies like metformin. Tricare’s Pharmacy & Therapeutics Committee reviews requests on a case-by-case basis, prioritizing cost-effective alternatives. If Wegovy is denied, patients can appeal with additional clinical evidence, such as records of hypoglycemic episodes or contraindications to other GLP-1 agonists. While Wegovy’s efficacy for diabetes is supported by trials like STEP 2, Tricare’s coverage remains restrictive to curb unnecessary spending.
Does Tricare Cover Wegovy for Weight Loss?
Tricare’s coverage of Wegovy for weight loss is limited and subject to stringent requirements. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥30 or ≥27 with weight-related comorbidities (e.g., hypertension, sleep apnea). However, Tricare typically excludes weight-loss medications from its formulary unless the patient meets exceptional criteria, such as a BMI ≥40 or a BMI ≥35 with severe obesity-related conditions.
Even if eligible, Wegovy coverage requires prior authorization. Providers must document a 6-12 month history of failed weight loss through diet, exercise, and behavioral therapy, along with evidence of obesity-related complications. Tricare may also require enrollment in a supervised weight-loss program. In 2026, Wegovy’s high cost ($1,300–$1,600/month without insurance) makes it a low priority for Tricare’s budget-conscious formulary. Patients often face denials unless they can prove Wegovy is medically necessary to prevent life-threatening conditions like heart disease or stroke.
How Much Does Wegovy Cost With Tricare?
The cost of Wegovy with Tricare varies by plan and eligibility. For diabetes patients approved under Tricare’s pharmacy benefits, Wegovy may be covered at Tier 3 or Tier 4, resulting in copays of $20–$60 per month for active-duty families or retirees. However, for weight loss, Wegovy is rarely covered, and patients typically pay the full retail price ($1,300–$1,600/month) unless they qualify for manufacturer savings programs.
Tricare Prime and Select beneficiaries face different cost-sharing structures. Active-duty service members may pay nothing if Wegovy is deemed medically necessary, while retirees and dependents could owe 20–25% of the drug’s cost under Tricare’s catastrophic cap. Without coverage, Wegovy’s price is prohibitive for most, though Novo Nordisk’s patient assistance program offers discounts (up to $500/month) for eligible individuals earning ≤400% of the federal poverty level. In 2026, Tricare’s reimbursement rates for Wegovy remain lower than commercial insurers, making out-of-pocket costs a significant barrier.
Wegovy Prior Authorization for Tricare
Securing Wegovy through Tricare requires a detailed prior authorization (PA) process. Providers must submit a PA request via the Tricare Pharmacy Benefit Manager (Express Scripts) or the patient’s regional contractor, including clinical notes, lab results, and proof of failed alternatives. For diabetes, the PA must show the patient’s A1C remains elevated despite adherence to other GLP-1 agonists (e.g., Ozempic) or SGLT2 inhibitors. For weight loss, the PA must document BMI, comorbidities, and a history of unsuccessful non-pharmacological interventions.
Tricare’s PA review typically takes 5–10 business days. If denied, providers can resubmit with additional evidence, such as records of weight-related hospitalizations or metabolic syndrome diagnoses. In 2026, Tricare has streamlined the PA process for Wegovy via its online portal, but approvals remain rare without compelling justification. Patients should ensure their provider includes all relevant data to avoid delays. If the PA is rejected, an appeal can be filed within 60 days, though success rates are low without new clinical developments.
How to Get Tricare to Cover Wegovy
To increase the chances of Tricare covering Wegovy, patients and providers must strategically navigate the approval process. First, ensure the patient meets Tricare’s strict criteria: for diabetes, uncontrolled A1C despite first-line therapies; for weight loss, a BMI ≥40 or ≥35 with severe comorbidities. Providers should document every failed intervention, including diet plans, exercise regimens, and prior medications.
Next, submit a comprehensive prior authorization (PA) request, including:
- A letter of medical necessity outlining why Wegovy is the only viable option.
- Lab results (e.g., A1C, lipid panels) and imaging (e.g., sleep study for apnea).
- Records of weight-loss program participation or diabetes education classes.
If the initial PA is denied, request a peer-to-peer review with a Tricare medical director. Highlight Wegovy’s FDA approval and its superiority over alternatives in clinical trials (e.g., STEP 1 for weight loss). For weight-loss cases, emphasize obesity’s impact on military readiness or service-related disabilities. Persistence and thorough documentation are key to overcoming Tricare’s cost-driven denials.
What to Do If Tricare Denies Wegovy
If Tricare denies Wegovy, patients have several recourse options. First, request a written denial letter outlining the reason (e.g., lack of medical necessity, formulary restrictions). Common denial codes include “non-covered service” or “experimental/investigational.” Next, file an appeal within 60 days via Tricare’s online portal or mail. The appeal should include:
- A rebuttal letter from the provider addressing Tricare’s concerns.
- New clinical evidence (e.g., updated lab results, records of worsening symptoms).
- Letters of support from specialists (e.g., endocrinologists, cardiologists).
For weight-loss denials, emphasize Wegovy’s role in preventing obesity-related complications like heart disease or joint damage. If the appeal is rejected, patients can escalate to a formal hearing with a Tricare hearing officer or request an external review by an independent medical expert. In 2026, Tricare’s appeals process remains bureaucratic, but persistence can yield approvals for patients with severe, refractory conditions. Alternatively, explore manufacturer savings programs or clinical trials for Wegovy access.
Tricare Alternatives If Wegovy Is Not Covered
If Tricare denies Wegovy, patients can explore alternative medications or cost-saving strategies. For diabetes, Tricare covers lower-cost GLP-1 agonists like Ozempic or Trulicity, which share Wegovy’s active ingredient (semaglutide) but at lower doses. For weight loss, phentermine (a generic appetite suppressant) is often covered but requires short-term use due to side effects. Other options include:
- Saxenda (liraglutide): A GLP-1 agonist approved for weight loss, though Tricare’s coverage is similarly restrictive.
- Contrave (naltrexone/bupropion): A non-GLP-1 weight-loss drug with lower efficacy but better coverage odds.
- Qsymia (phentermine/topiramate): A combination drug with moderate weight-loss benefits.
Patients can also reduce costs by:
- Using Novo Nordisk’s Wegovy savings card (up to $500/month for eligible patients).
- Switching to a Tricare plan with broader formulary access (e.g., Tricare Select vs. Prime).
- Enrolling in clinical trials for Wegovy or similar drugs. While alternatives may be less effective, they provide options when Tricare’s coverage falls short.
Frequently Asked Questions
Does Tricare cover Wegovy for weight loss?
Tricare rarely covers Wegovy for weight loss unless the patient has a BMI ≥40 or ≥35 with severe comorbidities (e.g., heart disease, sleep apnea). Even then, prior authorization is required, and denials are common due to Wegovy’s high cost. Patients must prove failed non-pharmacological interventions to qualify.
How much is the Wegovy copay with Tricare?
For diabetes patients, Wegovy copays range from $20–$60/month under Tricare’s pharmacy benefits. For weight loss, Wegovy is typically not covered, leaving patients to pay the full $1,300–$1,600/month unless they qualify for manufacturer discounts or patient assistance programs.
Can I appeal if Tricare denies Wegovy?
Yes, patients can appeal a Wegovy denial within 60 days by submitting additional clinical evidence, a provider’s letter of medical necessity, and records of failed alternatives. Appeals are reviewed by Tricare’s medical directors, but success rates are higher for diabetes cases than weight loss.
Disclaimer from Editorial Team: This article provides general information about Tricare’s coverage of Wegovy and is not a substitute for professional medical or legal advice. Coverage policies may change, and individual eligibility varies. Always consult Tricare or a healthcare provider for personalized guidance.